Matthew W Russell, Priya Shukla, Rishi P Singh, Katherine E Talcott
{"title":"抗凝治疗及其对视网膜静脉阻塞和眼内出血风险的影响","authors":"Matthew W Russell, Priya Shukla, Rishi P Singh, Katherine E Talcott","doi":"10.3928/23258160-20250523-01","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Management of hypercoagulable states with systemic anticoagulation is standard of care. The risk of future retinal vein occlusion (RVO) development with direct oral anticoagulation agents (DOACs) has yet to be investigated in a large United States cohort.</p><p><strong>Patients and methods: </strong>Retrospective cohort study using a large ICD-10 coded database. The database was queried for patients being managed with warfarin or DOACs. Propensity score matching was then used to create comparable groups. Risk ratios for RVO and intraocular bleed development in patients without a prior diagnosis of RVO were calculated.</p><p><strong>Results: </strong>Patients managed with warfarin were found to be at significantly increased risk of developing a new diagnosis of all RVO (risk ratio [RR]: 1.49, 1.42-1.57), vitreous hemorrhage (RR: 2.14, 1.98-2.30), retinal hemorrhage (RR: 1.84, 1.71-1.97) and choroidal hemorrhage (RR: 2.06, 1.53-2.79), compared to patients managed with DOACs.</p><p><strong>Conclusion: </strong>These findings suggest DOACs are associated with significantly reduced retinal vein occlusion and intraocular bleeding risk compared to warfarin. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2025;56:XX-XX.]</b>.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-6"},"PeriodicalIF":1.1000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anticoagulation Therapy and Influence on Retinal Vein Occlusion and Intraocular Bleeding Risk Across a Large US National Database.\",\"authors\":\"Matthew W Russell, Priya Shukla, Rishi P Singh, Katherine E Talcott\",\"doi\":\"10.3928/23258160-20250523-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Management of hypercoagulable states with systemic anticoagulation is standard of care. The risk of future retinal vein occlusion (RVO) development with direct oral anticoagulation agents (DOACs) has yet to be investigated in a large United States cohort.</p><p><strong>Patients and methods: </strong>Retrospective cohort study using a large ICD-10 coded database. The database was queried for patients being managed with warfarin or DOACs. Propensity score matching was then used to create comparable groups. Risk ratios for RVO and intraocular bleed development in patients without a prior diagnosis of RVO were calculated.</p><p><strong>Results: </strong>Patients managed with warfarin were found to be at significantly increased risk of developing a new diagnosis of all RVO (risk ratio [RR]: 1.49, 1.42-1.57), vitreous hemorrhage (RR: 2.14, 1.98-2.30), retinal hemorrhage (RR: 1.84, 1.71-1.97) and choroidal hemorrhage (RR: 2.06, 1.53-2.79), compared to patients managed with DOACs.</p><p><strong>Conclusion: </strong>These findings suggest DOACs are associated with significantly reduced retinal vein occlusion and intraocular bleeding risk compared to warfarin. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2025;56:XX-XX.]</b>.</p>\",\"PeriodicalId\":19679,\"journal\":{\"name\":\"Ophthalmic surgery, lasers & imaging retina\",\"volume\":\" \",\"pages\":\"1-6\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic surgery, lasers & imaging retina\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/23258160-20250523-01\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20250523-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Anticoagulation Therapy and Influence on Retinal Vein Occlusion and Intraocular Bleeding Risk Across a Large US National Database.
Background and objective: Management of hypercoagulable states with systemic anticoagulation is standard of care. The risk of future retinal vein occlusion (RVO) development with direct oral anticoagulation agents (DOACs) has yet to be investigated in a large United States cohort.
Patients and methods: Retrospective cohort study using a large ICD-10 coded database. The database was queried for patients being managed with warfarin or DOACs. Propensity score matching was then used to create comparable groups. Risk ratios for RVO and intraocular bleed development in patients without a prior diagnosis of RVO were calculated.
Results: Patients managed with warfarin were found to be at significantly increased risk of developing a new diagnosis of all RVO (risk ratio [RR]: 1.49, 1.42-1.57), vitreous hemorrhage (RR: 2.14, 1.98-2.30), retinal hemorrhage (RR: 1.84, 1.71-1.97) and choroidal hemorrhage (RR: 2.06, 1.53-2.79), compared to patients managed with DOACs.
Conclusion: These findings suggest DOACs are associated with significantly reduced retinal vein occlusion and intraocular bleeding risk compared to warfarin. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].
期刊介绍：
OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
